Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The lab will facilitate the development of herbal and natural-based solutions
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Subscribe To Our Newsletter & Stay Updated
